This site is intended for healthcare professionals
patient receiving dialysis, hospital image
Chronic Kidney Disease Learning Zone

Expert Opinion

Read time: 35 mins
Last updated:25th Apr 2022
Published:25th Apr 2022

In our series of expert videos on chronic kidney disease (CKD), Professor Hiddo Heerspink, Professor Vlado Perkovic and Dr George Bakris highlight:

  • The unmet needs and challenges in CKD, including underdiagnosis
  • The need for early CKD diagnosis and CKD screening strategies
  • The importance of managing comorbid conditions
  • CKD treatment goals and treatment options
  • Newly approved treatments for CKD, including SGLT2 inhibitors and mineralocorticoid receptor antagonists

Professor Hiddo Heerspink

Professor Hiddo Heerspink from the University Medical Centre Groningen in the Netherlands highlights key unmet needs and clinical challenges for chronic kidney disease (CKD) and describes the DAPA-CKD trial, which led to approval of dapagliflozin for treatment of diabetic and non-diabetic kidney disease.  

Screening for chronic kidney disease and common comorbidities
What is the evidence behind more recently approved treatments for CKD with and without diabetes?
Meet Professor Hiddo Heerspink and hear about his expertise in chronic kidney disease

Professor Vlado Perkovic

Professor Vlado Perkovic from the University of New South Wales in Australia discusses the burden of chronic kidney disease (CKD), management of comorbid conditions and the addition of canagliflozin to the treatment armamentarium for diabetic kidney disease following the CREDENCE trial.

What are the complications and burden of chronic kidney disease?
What are the concordant comorbidities and risk factors associated with chronic kidney disease?
What are the current recommendations for treating chronic kidney disease and preserving kidney function?
What are the recommendations for managing comorbidities in patients with chronic kidney disease?

Meet Professor Vlado Perkovic

Dr George Bakris

Dr George Bakris from the University of Chicago Medicine in the US outlines the priorities for managing chronic kidney disease and how new treatments, including finerenone, evaluated in the FIDELIO-DKD trial, can improve outcomes for patients with diabetic kidney disease.

What are the clinical challenges for managing chronic kidney disease and diabetic kidney disease?
Recent treatment options added to the treatment armamentarium for diabetic and non-diabetic kidney disease
Recommendations for managing comorbid conditions in patients at risk of chronic kidney disease
What are the priorities for treatment optimisation in chronic kidney disease?
Meet Dr George Bakris
Welcome: